Price
Target price
€2.20
€2.20
-3.510%
-0.08
-3.510%
€10.55
05.07.24 / Tradegate
WKN: A3DQSD / Symbol: CLRB / Name: Cellectar BioSciences / Stock / Pharmaceuticals / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cellectar BioSciences Inc. Stock
Heavy losses for Cellectar BioSciences Inc. today as the stock fell by -€0.080 (-3.510%).
With 7 Buy predictions and 6 Sell predictions the community is currently undecided on Cellectar BioSciences Inc..
Based on the current price of 2.2 € the target price of 10 € shows a potential of 354.55% for Cellectar BioSciences Inc. which would more than double the current price.
Pros and Cons of Cellectar BioSciences Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cellectar BioSciences Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Cellectar BioSciences Inc. | -3.510% | -5.172% | -23.077% | 18.919% | -3.509% | -78.846% | - |
Beximco Pharmaceuticals Ltd. GDR | - | 0.000% | 1.905% | 12.042% | -2.727% | -56.327% | 12.042% |
Arca Biopharma | -1.140% | 0.000% | 15.686% | 90.836% | 127.653% | 20.408% | -93.757% |
SELLAS Life Sciences Group Inc | 0.950% | 1.275% | -14.462% | -25.168% | 14.051% | -85.024% | -99.697% |
Comments
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Show more
Ratings data for CLRB provided by MarketBeat
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target raised by analysts at Roth Mkm from $20.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CLRB provided by MarketBeat
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock, up previously from $11.00.
Show more
Ratings data for CLRB provided by MarketBeat